Cara Therapeutics, Inc. (CARA)

Market Cap	21.26M
Revenue (ttm)	8.69M
Net Income (ttm)	-95.53M
Shares Out	4.57M
EPS (ttm)	-20.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,257
Open	4.680
Previous Close	4.600
Day's Range	4.510 - 4.790
52-Week Range	2.712 - 13.800
Beta	0.51
Analysts	Hold
Price Target	12.00 (+158.07%)
Earnings Date	Mar 3, 2025

About CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruish...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2014
• Employees: 55
• Stock Exchange: NASDAQ
• Ticker Symbol: CARA
• Website: https://www.caratherapeutics.com

Financial Performance

In 2023, Cara Therapeutics's revenue was $20.97 million, a decrease of -49.92% compared to the previous year's $41.87 million. Losses were -$118.51 million, 38.7% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for CARA stock is "Hold." The 12-month stock price forecast is $12.0, which is an increase of 158.07% from the latest price.

Price Target

$12.0

(158.07% upside)

Analyst Consensus: Hold